licensingBoehringer licenses PVT virus platform for cancer vaccinesBoehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines. more ➔
Start-upGraph Therapeutics raises $5m to advance I&I pipelineAustria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on … more ➔
fundraisingEG 427 rebrands as Cyllene and cashes in €33m Series CFrench gene therapy biotech EG 427 has rebranded as Cyllene Therapeutics and raised €33m in a Series C round to push its lead neuro-urology candidate EG110A toward late-stage clinical testing. more ➔
Scripta TherapeuticsOpinionWhere will AI actually move the needle in drug discovery?Biotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and … more ➔
NovartisM&ANovartis buys UK ADC biotech Myricx Bio in up to $1.5bn dealNovartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours. more ➔
licensingGenentech signs $490m breast cancer deal with AstexRoche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast … more ➔
licensingAstraZeneca returns to CSPC with $1.77bn kidney dealAstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases. more ➔
fundraisingOryzon raises €12m to push AML and CNS pipelineSpanish epigenetics biotech Oryzon Genomics has raised €12m in a capital increase and signed a financing agreement with COFIDES that could add another €25m in future share subscriptions. more ➔
Start-upTelum raises €18M to push phage-derived antimicrobials toward clinicSpanish biotech Telum Therapeutics has raised €18 million in Series A financing to move its lead antimicrobial programme toward clinical development. more ➔
financeAbivax cashes in on investor enthusiasm with €807m raiseAbivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative col … more ➔
Scripta Therapeutics
Novartis
